Pancreatic ductal adenocarcinoma (PDAC)
Clinical trials for Pancreatic ductal adenocarcinoma (PDAC) explained in plain language.
Never miss a new study
Get alerted when new Pancreatic ductal adenocarcinoma (PDAC) trials appear
Sign up with your email to follow new studies for Pancreatic ductal adenocarcinoma (PDAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Triple attack on pancreatic tumors: can radiation and immunotherapy make inoperable cancer operable?
Disease control Not yet recruitingResearchers test whether a short course of targeted radiation followed by the immunotherapy drug adebrelimab and NALIRIFOX chemotherapy can shrink locally advanced pancreatic cancer enough to allow surgery. The trial enrolls 36 adults with previously untreated pancreatic ductal a…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase 2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Old antiparasitic drug joins chemo in pancreatic cancer fight
Disease control Not yet recruitingResearchers at the University of Oklahoma are testing whether adding pentamidine, an antiparasitic drug, to standard modified FOLFIRINOX chemotherapy is safe and helps shrink tumors in people with advanced or metastatic pancreatic cancer. Up to 30 adults with confirmed locally ad…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase 1 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a smart drug outsmart pancreatic cancer?
Disease control Not yet recruitingThis phase III trial tests an experimental drug called YL201 against standard chemotherapy in people with metastatic pancreatic cancer that has progressed after gemcitabine-based treatment. YL201 is designed to deliver a toxin directly to cancer cells that carry a specific marker…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase 3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Experimental drug inavolisib targets Hard-to-Treat pancreatic cancer
Disease control Not yet recruitingThis phase 2 trial tests the drug inavolisib in people with pancreatic ductal adenocarcinoma whose cancer has worsened after prior chemotherapy. The study aims to see if inavolisib can shrink tumors or slow disease progression. Participants take inavolisib daily by mouth, and the…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug cocktail aims to tackle tough pancreatic cancer
Disease control Not yet recruitingThis study tests a new drug called becotatugvedotin combined with the chemotherapy gemcitabine for people with advanced pancreatic cancer that has not responded to first-line treatment. The trial has two phases: first, to find the safest dose of the new drug, and second, to see h…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase 1/2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New pill targets hard-to-treat cancers with KRAS G12D mutation
Disease control Not yet recruitingThis early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase 1 • Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug trial hopes to shrink Hard-to-Treat pancreatic tumors
Disease control Not yet recruitingThis phase II trial tests a drug called sacituzumab tirumotecan in 30 people with advanced pancreatic cancer that has worsened after at least one prior treatment. The drug is given by IV every two weeks. The main goal is to see if it can shrink tumors, and researchers will also t…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Targeted chemo delivery aims to boost pancreatic cancer surgery success
Disease control Not yet recruitingThis early-phase trial tests whether delivering the chemotherapy drug gemcitabine directly into the artery feeding the tumor can improve surgical outcomes for people with borderline resectable pancreatic cancer. Ten participants will receive standard chemo and radiation, followed…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase 1/2 • Sponsor: University of Vermont • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug aimed at slowing pancreatic cancer shows promise in early trial
Disease control Not yet recruitingThis study tests a new drug called HLX43 in 100 adults with advanced pancreatic cancer that has not responded to other treatments. The drug is designed to target and attack cancer cells while limiting harm to healthy cells. The goal is to see if it can shrink tumors or slow the d…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase 2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug cocktail aims to tackle tough gut cancers
Disease control Not yet recruitingThis Phase 2 trial will test an experimental drug called SSGJ-706 combined with standard chemotherapy (and sometimes another drug, bevacizumab) in 300 people with advanced gastrointestinal cancers that cannot be surgically removed. The goal is to see if the combination is safe an…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Phase 2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Scientists hunt for biomarkers to catch pancreatic cancer before it strikes
Diagnosis Not yet recruitingThis study aims to find molecular clues that could predict whether certain pancreatic growths will turn into cancer. Researchers will analyze tissue from patients having pancreatic surgery, using advanced genetic and protein tests on both the original tissue and lab-grown 3D cell…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
AI takes aim at pancreatic cancer: can it forecast chemotherapy outcomes?
Knowledge-focused Not yet recruitingThis observational study tests whether artificial intelligence can predict how well pancreatic cancer responds to chemotherapy and how the disease may progress. Researchers will analyze data from 700 patients, including endoscopic ultrasound images, CT/MRI scans, lab results, and…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
A phone call could unlock early cancer detection for High-Risk groups
Knowledge-focused Not yet recruitingThis study tests a remote education program to help people at higher risk for pancreatic cancer learn about genetic testing and a blood test that screens for multiple cancers. The program targets Black, Latino/a, and Medicaid-enrolled individuals in Massachusetts who may have had…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
New blood test may spot hidden pancreatic cancer earlier after surgery
Knowledge-focused Not yet recruitingThis study looks at whether a new blood test can find tiny bits of tumor DNA left behind after pancreatic cancer surgery. About 30 adults who had their cancer removed will give blood samples at three key times over six months. The goal is to see if this test can detect remaining …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: Chang Gung Memorial Hospital • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Gut bugs and blood clues may guide pancreatic cancer therapy
Knowledge-focused Not yet recruitingThis study aims to find biological markers in the blood, immune system, and gut microbiome that can help doctors choose the best treatment for people with advanced pancreatic cancer that cannot be removed by surgery. Researchers will collect blood and stool samples from 140 parti…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: Chang Gung Memorial Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Bile drain before pancreatic surgery: help or hindrance?
Knowledge-focused Not yet recruitingThis study looks at whether draining a blocked bile duct before surgery for pancreatic cancer changes the tumor's behavior or patient survival. Researchers will review medical records of 90 patients who had their pancreatic tumor removed over 8 years. They will compare those who …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
Sponsor: East Lancashire Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC